1 The most frequently reported grade 3 or higher
adverse events were abnormal blood chemistry results (33 [15%
2 Progression-free survival (PFS), OS, and
adverse events were also assessed.
3 The most common grade 3-4 treatment-related
adverse events were anaemia (four [4%]) and infusion-related
4 contrast sensitivity, endothelial cell count, and possible
adverse events were assessed at least 12 months postoperative
5 Adverse events were assessed for up to 28 days.
6 Serious
adverse events were assessed in all women who received at lea
7 Adverse events were assessed up to 28 days.
8 No serious
adverse events were attributed to dihydroartemisinin-piperaqu
9 All patients had engraftment, and
adverse events were consistent with effects of the preparativ
10 Such
adverse events were dose-dependent and were more common after
11 The most common drug-related
adverse events were fatigue, nausea, diarrhea, anorexia, vomi
12 The most common grade 3-4
adverse events were febrile neutropenia (22 [66%]), bloodstre
13 Other
adverse events were grade 1 or 2 neurotoxicity in eight patie
14 The most common (n>1) drug-related
adverse events were headache (in nine [30%] participants) and
15 The most common grade 3 or 4
adverse events were hypertension (88 [27%] of 332 patients in
16 11.41-13.94) per 100 patient-years; the most common serious
adverse events were infections at 4.13 (95% CI 3.45-4.91) per
17 Drug-related
adverse events were less common with rifampin than isoniazid
18 All treatment-related
adverse events were mild or moderate in severity and similar
19 Most
adverse events were mild.
20 Adverse events and serious
adverse events were minimal, but 2 deaths (7.4%) occurred tha
21 Systemic
adverse events were more common after the second vaccination,
22 Serious
adverse events were more common with systematic treatment.
23 Adverse events were more common with zoledronic acid than wit
24 Treatment-emergent
adverse events were most frequent in the highest dose group.
25 Adverse events were mostly mild and equally distributed (15/2
26 Adverse events were mostly mild or moderate and none were ser
27 The most common
adverse events were neck or arm or shoulder pain, arm paraest
28 The most common treatment-related grade 3-4
adverse events were neutropenia (15 [50%] of 30 patients), in
29 The most common any-cause grade 3 or worse
adverse events were neutropenia (85 [32%] of 266 patients in
30 Intraoperative and postoperative
adverse events were noted.
31 Lumbar puncture-related
adverse events were observed in most participants.
32 The most common grade 3-4
adverse events were raised gamma-glutamyltransferase (13 [16%
33 99m)Tc-PHC-102 was well tolerated and no study drug-related
adverse events were recorded.
34 No serious
adverse events were related to vaccination.
35 Two serious
adverse events were reported - both resolved without sequelae
36 Solicited
adverse events were reported by 44% of vaccine recipients and
37 Serious
adverse events were reported for 18 (8%) patients in the treo
38 Adverse events were reported in 108 (69%) of 156 patients in
39 Treatment-emergent
adverse events were reported in 122 (53%) of 230 patients in
40 Serious
adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) pa
41 Adverse events were reported in 58.4% of patients; most (94.4
42 Serious
adverse events were reported in five (3%) of 156 patients in
43 Eight serious
adverse events were reported with capsular release and two wi
44 No severe vaccine-related
adverse events were reported.
45 Serious
adverse events were similar between groups (112 [43%] of 258
46 Cumulative rates of serious
adverse events were similar in TAK-003 (4.0%) and placebo (4.
47 Adverse events were similar in the two trial groups, with no
48 Reports of
adverse events were similar to those of previous ixekizumab s
49 up; the most common (>=20% patients in any group) grade 3-4
adverse events were thrombocytopenia (33 [42%] of 78, 26 [31%
50 Serious procedure-related
adverse events were uncommon.